Dailey Trader Reports

Dear Dailey Traders,

Our buy recommendation and Pick for 2013 is a Medical Device company that is up and coming:

Sanomedics International Holdings, Inc. (“ SIMH ”), make sure you drop what you're doing right now and put your full focus on our New Pick SMIH. We're expecting SIMH to have some massive days and weeks ahead of it so make sure to act fast on this one starting now.  SIMH just announced the closing of Prime Time Medical, Inc., of Largo, Florida ("Prime Time").

Sanomedics Announces Completion of Prime Time Medical Acquisition

MIAMI, September 3, 2013 /PRNewswire/ -- Sanomedics International Holdings, Inc. (OTCQB:  SIMH ) ("Sanomedics"), a medical technology holding company that focuses on game-changing products, services and ideas, today announced that it has completed the previously announced acquisition of Prime Time Medical, Inc., of Largo, Florida ("Prime Time") for a total purchase price of $3,100,000, effective August 30, 2013. The closing price was amended to include the issuance of 531,250 common shares of Sanomedics, $1 million in debt, and $1,250,000 cash consideration with $400,000 paid through closing and the balance of $850,000 in a promissory note payable within 30 days.  And the company is about to take off flying.

Sanomedics International Holdings, Inc. (“ SIMH ”),  www.sanomedics.com , Talk with management at  @sanomedics .  Sanomedics International Holdings, Inc. is a medical technology holding company that focuses on game changing products, services and ideas – a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. We plan to grow our existing business organically and through strategic acquisitions specifically relating to sleep disorder diagnosis treatments. “Sanomedics” seeks to acquire sleep therapy operating businesses and our strategy is to integrate a portfolio of world-class products and service providers in the growing Sleep Apnea market. Our goal is to provide Sleep Apnea patients with a reliable and integrated “end-to-end” service platform.

Source:  http://www.fool.com/ Contributor Dan Carrol August 31, 2013

“You may not think of medical device makers as some of the most profitable companies on the markets, but make no mistake -- this industry's top players aren't shy about bringing in top profits. Small, niche companies and powerhouses alike have been able to capitalize on the rising demand for health care to generate strong bottom lines and reward investors handsomely for their gains.”  Continue reading at;  http://www.fool.com/investing/general/2013/08...anies.aspx

We’ve selected “ SIMH ” as our long term play for its management team, as well as its technical and strategic posturing. We wouldn’t at all be surprised if over the long term “ SIMH ” emerges as defining company inside the Medical device industry and Sleep Apnea Market.  As well as growth of their thermo medic technology.  Let’s not forget about their portfolio of savvy investors. So grab your investing hats folks and prepare to add some serious credibility to your long term portfolio, “ SIMH ” is sure to add some value.  Do your homework!

Thermomedics, Inc. “ SIMH ” designs, develops and markets medical diagnostic equipment for professional healthcare providers. Our products are professionally designed for use in a wide range of medical settings, providing nearly instantaneous diagnostic information. Our goal was simple from the start. We wanted to build the best equipment and bring cutting edge technology to frontline medical professionals… Ease of Use…Peace of Mind…

Health Care Facts:

•          Americans spent $2.6 trillion on health care in 2010 -- ten times more than in 1980.

•          Home Health Care services as per May 2012 by The United States Department of Labor estimate that almost 3 million are employed full time in the United States. On a whole by 2020, the ranks of home health and personal care aides will have swelled by more than 6 million jobs from 2012, according to the Bureau of Labor Statistics and growing at twice the rate of the national economy.

•          About 4% of U.S. adults aged 20 and over used sleep aids in the past month.

•          One in six adults with a diagnosed sleep disorder and one in eight adults with trouble sleeping reported using sleep aids.

•          According to estimates, 50–70 million Americans suffer from sleep disorders or deprivation, which can not only hinder daily functioning, but can also adversely, affect their health. (Reference: Yinong Chong, Cheryl D. Fryar, and Qiuping Gu are with the Centers for Disease Control and Prevention's National Center for Health Statistics, Division of Health and Nutrition Examination Surveys.)

Highlights:  
SIMH ’s current market valuation has plenty of room for long term growth. This means of course that bullish long term sentiments have yet to push “ SIMH ” to its more natural levels.   SIMH has been consolidating well in recent months and the company’s long term RSI is a healthy 30. There is therefore plenty of scope for long term growth and investors can have confidence in the risk profile of SIMH.   SIMH recently signed a letter of intent for $5 million in senior debt financing.   SIMH has embarked on an ambitious acquisition strategy in a highly fragment Healthcare space.

This Press Release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements provisions contained in the Private Securities Litigation Reform Act of 1995 and any amendments thereto. Such forward-looking statements by definition involve risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. In particular, there is no assurance that reserves, production, pricing levels or other factors pertaining to the oil and gas operations will be sustained at the expected rates or levels over time. Discussions of factors, which may affect future results, are contained in our recent filings. Under no circumstances does this Press Release constitute an offer to sell or a solicitation of an offer to buy the securities of the company described in this Press Release in which such offer, solicitation or sale of securities would be unlawful prior to registration, qualification or filing under the securities laws of any jurisdiction. Compensation for dissemination of this report 50,000 restricted shares via Sandomedics International Holdings. To opt-out list@firstfinancialnews.com